Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation | MicrobiomeTrials← Back to trialsNCT05672173
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2023-06-02Est. Completion: 2026-09-10
Enrollment target: 9 participants Locations- City of Hope Medical Center, Duarte, California, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
Other microbiome trials you might be interested in
Hematologic Cancer
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood …
Tempe, United StatesEst. completion Mar 2031
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory B-Cell Non-Hodgkin LymphomaRefractory Chronic Lymphocytic Leukemia
Refractory Small Lymphocytic Lymphoma
Refractory Transformed Chronic Lymphocytic Leukemia
This phase I trial studies the effects of CD-19 directed chimeric antigen receptor (CAR)-T cell therapy for the treatmen…
Rochester, United StatesEst. completion Mar 27, 2028